Cogent Biosciences (COGT) Research & Development (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Research & Development of $75.4 million for Q1 2026, up 19.57% year-over-year from $63.0 million in Q1 2025, and little changed quarter-over-quarter from $75.6 million in Q4 2025.
Cogent Biosciences (COGT) Research & Development (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Research & Development for 10 consecutive years, with $75.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 19.57% year-over-year to $75.4 million; the TTM figure through Mar 2026 stood at $282.1 million (up 16.11% YoY), while the FY2025 annual figure was $269.8 million, up 15.96% from the prior year.
- Research & Development steadied at $75.4 million in Q1 2026 per COGT's latest filing, from $75.6 million in the prior quarter.
- Across five years, Research & Development topped out at $75.6 million in Q4 2025 and bottomed at $25.5 million in Q1 2022.
- Historically, Research & Development has averaged $51.4 million across 5 years, with a median of $52.7 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development soared 210.12% — and 2025, when it increased 8.45%.
- Cogent Biosciences' Research & Development stood at $36.7 million in 2022, then soared by 32.6% to $48.7 million in 2023, then gained by 27.35% to $62.0 million in 2024, then gained by 21.78% to $75.6 million in 2025, then retreated by 0.26% to $75.4 million in 2026.
- Business Quant data shows COGT's Research & Development at $75.4 million in Q1 2026, $75.6 million in Q4 2025, and $69.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 70.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.81 Mn |
| Mar 31, 2026 | 75.37 Mn |
| Dec 31, 2025 | 75.56 Mn |
| Sep 30, 2025 | 68.99 Mn |
| Jun 30, 2025 | 62.20 Mn |
| Mar 31, 2025 | 63.03 Mn |
| Dec 31, 2024 | 62.05 Mn |
| Sep 30, 2024 | 63.61 Mn |
| Jun 30, 2024 | 54.29 Mn |
| Mar 31, 2024 | 52.71 Mn |
| Dec 31, 2023 | 48.72 Mn |
| Sep 30, 2023 | 50.13 Mn |
| Jun 30, 2023 | 38.87 Mn |
| Mar 31, 2023 | 36.04 Mn |
| Dec 31, 2022 | 36.74 Mn |
| Sep 30, 2022 | 29.94 Mn |
| Jun 30, 2022 | 29.48 Mn |
| Mar 31, 2022 | 25.47 Mn |
| Dec 31, 2021 | 20.51 Mn |
| Sep 30, 2021 | 14.80 Mn |